Autopsy report · NCT03880955

A Post-Market Clinical Evaluation of the ReUnion Reverse Shoulder Arthroplasty (RSA) System

“Sponsor decision to stop at 2 year follow-up”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years 6 months before it stopped.
• 102 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Sponsor

Stryker Trauma and Extremities

Sponsor type

Industry

Conditions

Shoulder Arthroplasty

Interventions

ReUnion RSA System

Participants

102

Sites

3

Countries

United States

Trials that died the same way

• The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
  “Sponsor Decision to discontinue long-term follow-up” (87% match in meaning)
• SURF, Neurodevelopment, Growth Study in SGA Infants
  “Sponsor decision stopped in June 2017” (80% match in meaning)
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
  “Sponsor chose not to continue” (77% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (73% match in meaning)
• Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
  “stopped by sponsor” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.